Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Study of Cytokine Release Syndrome Prophylaxis With Infliximab for Teclistamab/Talquetamab Therapy in Patients With Relapsed/Refractory Myeloma

NCT07657312 is registered in ClinicalTrials.gov with Naresh Bumma as lead sponsor.

NCT NCT07657312
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07657312 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Study of Cytokine Release Syndrome Prophylaxis With Infliximab for Teclistamab/Talquetamab Therapy in Patients With Relapsed/Refractory Myeloma
Lead sponsor
Naresh Bumma
Phase
Phase 2
Overall status
Recruiting
Start date
July 17, 2026
Completion date
December 31, 2027
Enrollment
35 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cytokine release syndrome, recurrent multiple myeloma, refractory multiple myeloma